A BCC8/SUR1-activating mutations induce neonatal diabetes (1) or other diabetes (1) (2) (3) (4) . Sulfonylurea treatment is unsuccessful in 15% patients (2, 3) . Glucagon-like peptide 1 (GLP-1) enhances insulin secretion by activating diverse signaling pathways (4) . This study aimed at exploring if the GLP-1 effect is retained when b-cell dysfunction is related to ABCC8 mutation.
Three informed patients were included after approbation by the local ethics com- Explorations were performed during a prolonged oral glucose tolerance test (OGTT; 75 g glucose) at 9 A.M., in three conditions. For the "no treatment condition," usual hypoglycemic treatment was stopped during 3 days. Diabetes was controlled with a subcutaneous insulin infusion (Lispro insulin; Eli Lilly, Indianapolis, IN), which was stopped 4 h before OGTT. For the "sulfonylurea condition," patients were taking their usual sulfonylurea treatment, and patient 3 stopped metformin and exenatide for 2 days. Patients were given 5 mg glyburide in addition to their usual sulfonylurea treatment 30 min before OGTT. For the "exenatide condition," usual hypoglycemic treatment was stopped for 4 days. Diabetes was controlled with a subcutaneous insulin infusion which was stopped 4 h before OGTT. Patients were given 10 mg exenatide (Byetta; Eli Lilly) 15 min before OGTT.
In absence of treatment, the three patients had a frank diabetic glycemic profile (time 120 min [T120] glycemic level: 18, 25, and 22 mmol/L) with a low maximal C-peptide level at T120 (1.1, 1, and 0.8 nmol/L, for normal range at fasting: 0.3 to 1.4 nmol/L). Under sulfonylurea, early C-peptide modestly increased in patient 1 (D 30 min 0.7 nmol/L), leading only in this patient to a moderate decrease of glycemic level. Surprisingly, sulfonylurea induced increase of glucagon level during OGTT. Conversely after injection of 10 mg exenatide, C-peptide level increased to a maximal level at T120 (1.7, 1.5, and 2.8 nmol/L), glucagon concentration was obviously decreased (D area under the curve glucagon 21, 21, 23.5 pg/mL/min), and glycemic level decreased to a minimal level at T120 (4, 9, and 5 mmol/L).
In conclusion, exenatide incretin effect was highly preserved despite ABCC8-related b-cell dysfunction. C-peptide concentration was increased at the same level as described in type 2 diabetes (5). This suggests that GLP-1 can facilitate the closure of the ATP-sensitive K 1 channel despite activating ABCC8 mutation. Overall exenatide induced a great improvement of post OGTT glycemic excursion. We suggest that patients with ABCC8 mutation who are not being successfully transferred from insulin to sulfonylurea could benefit from GLP-1 receptor agonist treatment, at least if they have some residual C-peptide secretion. 
